Eagle Pharmaceuticals (FRA:1E6) Total Stockholders Equity : €232.6 Mil (As of Jun. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Eagle Pharmaceuticals Total Stockholders Equity?

Eagle Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Jun. 2023 was €232.6 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Eagle Pharmaceuticals's Book Value per Share for the quarter that ended in Jun. 2023 was €17.77. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Eagle Pharmaceuticals's Debt-to-Equity for the quarter that ended in Jun. 2023 was 0.28.

Eagle Pharmaceuticals Total Stockholders Equity Historical Data

The historical data trend for Eagle Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eagle Pharmaceuticals Total Stockholders Equity Chart

Eagle Pharmaceuticals Annual Data

Trend

Sep13

Sep14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Stockholders Equity

Get a 7-Day Free Trial

141.31

161.26

152.90

156.16

220.48

Eagle Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Total Stockholders Equity	Get a 7-Day Free Trial															225.13	234.10	220.48	226.82	232.63

Eagle Pharmaceuticals (FRA:1E6) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Eagle Pharmaceuticals's Book Value per Share for the quarter that ended in Jun. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(232.633	-	0)	/	13.0947
	=	17.77

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Eagle Pharmaceuticals's Debt-to-Equity for the quarter that ended in Jun. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(8.971	+	57.13)	/	232.633
	=	0.28

Eagle Pharmaceuticals Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Eagle Pharmaceuticals's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Eagle Pharmaceuticals (FRA:1E6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eagle Pharmaceuticals Inc (FRA:1E6) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

EGRX:USA

Address

50 Tice Boulevard, Suite 315, Woodcliff Lake, NJ, USA, 07677

Website

http://www.eagleus.com

Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.

Eagle Pharmaceuticals (FRA:1E6) Headlines

No Headlines